Patents by Inventor Scott Hammond
Scott Hammond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210177931Abstract: Provided is a method for treating cancer by administering to an individual who has the cancer a MAD1 peptide. The peptide can enhance the effect of a chemotherapeutic agent that is administered to the individual in combination with the peptide.Type: ApplicationFiled: February 22, 2021Publication date: June 17, 2021Inventors: Scott Hammond MEDINA, Andrew William SIMONSON, Matthew ARONSON
-
Publication number: 20210017282Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.Type: ApplicationFiled: July 23, 2019Publication date: January 21, 2021Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOCK, IAN FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWART, KATHLEEN ANN MULGREW
-
Publication number: 20200311300Abstract: The present disclosure relates to techniques for developing artificial intelligence algorithms by distributing analytics to multiple sources of privacy protected, harmonized data. Particularly, aspects are directed to a computer implemented method that includes receiving an algorithm and input data requirements associated with the algorithm, identifying data assets as being available from a data host based on the input data requirements, curating the data assets within a data storage structure that is within infrastructure of the data host, and integrating the algorithm into a secure capsule computing framework. The secure capsule computing framework serves the algorithm to the data assets within the data storage structure in a secure manner that preserves privacy of the data assets and the algorithm. The computer implemented method further includes running the data assets through the algorithm to obtain an inference.Type: ApplicationFiled: March 26, 2020Publication date: October 1, 2020Inventors: Rachael CALLCUT, Michael Blum, Joe Hesse, Robert D. Rogers, Scott Hammond, Maryelizabeth Chalk
-
Patent number: 10713747Abstract: A method in a multi-core processing system for generating graphical commands is provided. The method includes generating a unique layer task for each of a plurality of layers that forms the current display frame in a cockpit display system (CDS), wherein the CDS is configured to display a plurality of windows, each window includes a plurality of layers, each layer includes one or more widgets that belong to a single user application, and each layer task includes information for a processor core in the multi-core processing system to generate graphical commands that when executed cause the rendering of the graphics described by the layer. The method further includes executing a plurality of layer tasks in parallel by a plurality of the processor cores in the multi-core processing system to generate graphical commands for execution by a GPU to render another display frame in the CDS.Type: GrantFiled: June 8, 2018Date of Patent: July 14, 2020Assignee: HONEYWELL INTERNATIONAL INC.Inventors: Richard Wendlandt, Edward Colin Layden, Scott Hammond, Kannan Kathirvel, Adam Folts
-
Publication number: 20200179287Abstract: The present invention relates in part to novel drug delivery particles comprising an anionic polymer matrix and a cationic polymer, wherein the anionic polymer matrix and cationic polymer together form drug delivery particles bound by electrostatic interactions and wherein the drug delivery particles comprise at least one biologically active agent. The invention also relates in part to a method of treating a mycobacterial infection using said drug delivery particles, and a method of making said drug delivery particles.Type: ApplicationFiled: June 5, 2018Publication date: June 11, 2020Applicant: The Penn State Research FoundationInventors: Scott Hammond MEDINA, Andrew William SIMONSON
-
Publication number: 20200172622Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: ApplicationFiled: September 13, 2019Publication date: June 4, 2020Inventors: SRINATH KASTURIRANGAN, CHANGSHOU GAO, GODFREY RAINEY, MICHELLE MORROW, CLAIRE LOUISE DOBSON, STACEY DRABIC, DARREN SCHOFIELD, GIANLUCA CARLESSO, KRISTEN POLLIZZI, YARIV MAZOR, MICHAEL OBERST, SCOTT A. HAMMOND, BRIAN LOBO, PRAKASH MANIKWAR, JONATHAN SEAMAN, SIMON DOVEDI, RONALD HERBST
-
Publication number: 20200079877Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: ApplicationFiled: November 8, 2019Publication date: March 12, 2020Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui Huang, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
-
Patent number: 10556968Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: GrantFiled: April 4, 2019Date of Patent: February 11, 2020Assignee: MEDIMMUNE LIMITEDInventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
-
Publication number: 20190378236Abstract: A method in a multi-core processing system for generating graphical commands is provided. The method includes generating a unique layer task for each of a plurality of layers that forms the current display frame in a cockpit display system (CDS), wherein the CDS is configured to display a plurality of windows, each window includes a plurality of layers, each layer includes one or more widgets that belong to a single user application, and each layer task includes information for a processor core in the multi-core processing system to generate graphical commands that when executed cause the rendering of the graphics described by the layer. The method further includes executing a plurality of layer tasks in parallel by a plurality of the processor cores in the multi-core processing system to generate graphical commands for execution by a GPU to render another display frame in the CDS.Type: ApplicationFiled: June 8, 2018Publication date: December 12, 2019Applicant: HONEYWELL INTERNATIONAL INC.Inventors: Richard Wendlandt, Edward Colin Layden, Scott Hammond, Kannan Kathirvel, Adam Folts
-
Patent number: 10457732Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: May 5, 2017Date of Patent: October 29, 2019Assignee: MEDIMMUNE, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
-
Publication number: 20190292274Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: ApplicationFiled: April 4, 2019Publication date: September 26, 2019Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui HUANG, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
-
Patent number: 10400039Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.Type: GrantFiled: October 25, 2016Date of Patent: September 3, 2019Assignee: MEDIMMUNE LIMITEDInventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
-
Publication number: 20190241659Abstract: Provided herein are bispecific fusion proteins and methods of using the bispecific fusion proteins for treating cancer.Type: ApplicationFiled: November 8, 2018Publication date: August 8, 2019Inventors: JOHN MUMM, YUE WANG, RYAN GILBRETH, RONALD HERBST, SCOTT HAMMOND, MICHAEL OBERST, GODFREY JONAH RAINEY, SIMON DOVEDI, JONATHAN SEAMAN, MICHELLE TURNHAM
-
Publication number: 20190169303Abstract: The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.Type: ApplicationFiled: December 10, 2018Publication date: June 6, 2019Inventors: Scott A. Hammond, Michael Oberst, Qun Du, Melissa Damschroder
-
Patent number: 10287362Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: GrantFiled: February 23, 2018Date of Patent: May 14, 2019Assignee: MedImmune LimitedInventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
-
Patent number: 10150815Abstract: The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.Type: GrantFiled: June 28, 2017Date of Patent: December 11, 2018Assignee: MEDIMMUNE, LLCInventors: Scott A. Hammond, Michael Oberst, Qun Du, Melissa Damschroder
-
Publication number: 20180194858Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: ApplicationFiled: February 23, 2018Publication date: July 12, 2018Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui Huang, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
-
Patent number: 9938356Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.Type: GrantFiled: November 9, 2015Date of Patent: April 10, 2018Assignee: MEDIMMUNE LIMITEDInventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
-
Publication number: 20180072808Abstract: The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.Type: ApplicationFiled: June 28, 2017Publication date: March 15, 2018Inventors: SCOTT A. HAMMOND, MICHAEL OBERST, QUN DU, MELISSA DAMSCHRODER
-
Publication number: 20180022807Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: ApplicationFiled: May 5, 2017Publication date: January 25, 2018Applicant: MEDIMMUNE, LLCInventors: Srinath KASTURIRANGAN, CHANGSHOU GAO, GODFREY RAINEY, MICHELLE MORROW, CLAIRE LOUISE DOBSON, STACEY DRABIC, DARREN SCHOFIELD, GIANLUCA CARLESSO, KRISTEN POLLIZZI, YARIV MAZOR, MICHAEL OBERST, SCOTT A. HAMMOND, BRIAN LOBO, PRAKASH MANIKWAR, JONATHAN SEAMAN